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Aim: To develop a diagnostic DNA chip to detect mutations in
the bigh3 gene causing the most common corneal dystrophies
(CDs).
Methods: Samples from 98 people, including patients with
bigh3-associated CDs (b-aCDs), were examined. Specific
primer and probe sets were designed to examine exons 4
and 12 of the bigh3 gene, in order to identify mutant and wild-
type alleles. Mutations were then identified by hybridisation
signals of sequence-specific probes immobilised on the slide
glass.
Results: Direct sequencing of exons 4 and 12 of the bigh3 gene
in the patients’ genome showed that b-aCDs could be mainly
classified into five types: homozygotic Avellino corneal
dystrophy (ACD), heterozygotic ACD, heterozygotic lattice
CD I, heterozygotic Reis–Bucklers CD and heterozygotic
granular CD. Blind tests were performed by applying the
target DNA amplified from the genomic DNA isolated from the
peripheral blood of the participants onto a DNA chip. The
results obtained by DNA chip hybridisation matched well with
the direct DNA sequencing results.
Conclusions: The DNA chip developed in this study allowed
successful detection of b-aCDs with a sensitivity of 100%.
Mutational analysis of exons 4 and 12 of the bigh3 gene, which
are the mutational hot spots causing b-aCDs, can be
successfully performed with the DNA chip. Thus, this DNA
chip-based method should allow a convenient, yet highly
accurate, diagnosis of b-aCDs, and can be further applied to
diagnose other types of CDs.
G
enetic analyses of most common bigh3-associated
corneal dystrophies (b-aCDs) such as Avellino corneal
dystrophy (ACD), Reis–Bucklers CD (RBCD), lattice CD
type I (LCD I) and granular CD (GCD) have shown that most
cases are caused by amino acid substitutions within the bigh3
gene. In the case of ACD, the 124th amino acid arginine of the
bigh3 protein is substituted by histidine. Similarly, LCD I is
caused by R124C, whereas RBCD is caused by R124L. GCD (also
called GCD I) is caused by R555W.1–3 Thus, molecular genetic
analysis of the mutations in the bigh3 gene is most adequate to
diagnose patients having different types of b-aCDs, in particular
those with an atypical or ambiguous corneal appearance.4–6
The molecular genetic analysis of the mutations in the bigh3
gene has mainly relied on direct sequencing. However, DNA
microarray-based detection of point mutations can be a much
more efficient alternative. To analyse the point mutation in a
gene by direct sequencing, the DNA fragment containing a
mutated site is amplified and extracted with high purity before
sequencing. Even when using the automatic DNA sequencer,
each signal peak should be checked directly from the raw data
to find just a single gene mutation. This sequential work is
rather cumbersome and takes 24–48 h. DNA microarray-based
assay can be a simple but powerful alternative, as it allows
simultaneous handling of multiple samples and sequences7 and
requires only a small amount of the amplified product that can
be directly applied onto a DNA chip without any purification
step. It takes no more than 6–8 h, and analysis can be
performed simply by checking the signal on the expected probe
spot regions. In this paper, we report the development of a DNA
chip for detection of the mutations in the bigh3 gene, which
allows rapid, convenient and accurate diagnosis of b-aCDs.
MATERIALS AND METHODS
Patients and collection of samples
This study was performed in accordance with the Helsinki
Agreement, and all participants gave their informed consent
before the test, which was approved by Severance Hospital IRB
Committee (No 4-2006-0075).
DNA sequence analysis
DNA was extracted from the peripheral blood of participants
with the JETQUICK Blood & Cell Culture DNA Spin Kit
(GENOMED GmbH, Lo¨hne, Germany). Exons 4 and 12 of the
bigh3 gene were amplified by PCR with origin of replication
(Ori) 4 primer sets and Ori 12 primer sets, respectively (table 1
and fig 1). The PCR was conducted with a PCR thermal cycler
T1 (BioMetra GmbH, Gottingen, Germany). The amplified
products were purified with a PCR purification kit (Qiagen,
Hilden, Germany). For the verification of mutations and
identification of the mutation types, the DNA isolated from
all the 98 participants were also sequenced with an automatic
Abbreviations: ACD, Avellino corneal dystrophy; b-aCD, bigh3-
associated corneal dystrophy; CD, corneal dystrophy; FITC, fluorescein
isothiocyanate; GCD, granular CD; LCD I, lattice CD type I; Ori, origin of
replication; RBCD, Reis–Bucklers CD; SSPE, saline/sodium phosphate/
EDTA
Table 1 Primers used in this study
Primer name Sequence (59R39)
Ori 4 Forward CCCCAGAGGCCATCCCTCCT
Ori 4 Reverse CCGGGCAGACGGAGGTCATC
Ori 12 Forward CATTCCAGTGGCCTGGACTCTACTATC
Ori 12 Reverse GGGGCCCTGAGGGATCACTACTT
ACD Forward AGCCCTACCACTCTCAA
ACD Reverse CAGGCCTCGTTGCTAGGG
ACD, Avellino corneal dystrophy; Ori, origin of replication.
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DNA sequencer (ABI Prism 377, Applied Biosystems, Foster,
California, USA).
Microarray fabrication
The 39 termini of designed probes were modified with amine
residues using an amino-linker column (Cruachem, Glasgow,
Scotland) for their immobilisation on the aldehyde-coated slide
glasses (CEL Associates, Huston, Texas, USA) by forming amine–
aldehyde covalent bonds. The 15mer-poly A oligonucleotide
labelled with fluorescent dyes such as Cy3, Cy5 or fluorescein
isothiocyanate (FITC) was used as position marker. The 11mer,
13mer, 15mer and 17mer probes were designed and tested for
their efficiencies in detecting the mutations. The probes were
resuspended in 36 saline sodium citrate spotting solution
(0.45 M NaCl, 15 mM C6H5Na3O7, pH 7.0) and spotted on the
slide glass using MicroGridII (BioRobotics, Cambridge, UK).
After spotting, the slide glasses were air dried at room
temperature for 12 h or baked at 80˚ C for 1 h.
Figure 1 Gene maps and haplotypes of the
bigh3 gene. Coding exons are marked by
black bars. PCR primers used for the
amplification of the targets and the amplified
products are shown. Arrows indicate the
mutational hot spots in exons 4 and 12 of the
common bigh3-associated corneal
dystrophies. ACD, Avellino corneal
dystrophy; Fw, forward; GCD, granular
corneal dystrophy; LCD, lattice corneal
dystrophy; Ori, origin of replication; RBCD,
Reis–Bucklers corneal dystrophy; Re, reverse.
Table 2 Probes designed for detecting the mutations in the bigh3 gene
n* Mutations Probe name Length Sequences (59–39)
Exon
number Disease
1 R124 Not ACD
(4-CGC)
11 GGACCGCACGG 4 Normal/heterozygotic
13 CGGACCGCACGGA
15 ACGGACCGCACGGAG
17 CACGGACCGCACGGAGA
2 R124 Not LCD I
(4-CGC)
11 CGGACCGCACG 4 Normal/heterozygotic
13 ACGGACCGCACGG
15 CACGGACCGCACGGA
17 ACACGGACCGCACGGAG
3 R124H ACD
(4-CAC)
11 GGACCACACGG 4 ACD
13 CGGACCACACGGA
15 ACGGACCACACGGAG
17 CACGGACCACACGGAGA
4 R124C LCD I
(4-TGC)
11 CGGACTGCACG 4 LCD I
13 ACGGACTGCACGG
15 CACGGACTGCACGGA
17 ACA CGG ACT GCA CGG AG
5 R124L RBCD
(4-CTC)
11 GGACCTCACGG 4 RBCD
13 CGGACCTCACGGA
15 ACGGACCTCACGGAG
17 CACGGACCTCACGGAGA
6 R555 Not GCD
(12-CGG)
15 AAGAGAACGGAGCAG 12 Normal/heterozygotic
17 CAAGAGAACGGAGCAGA
16 CAAGAGAACGGAGCAG
16 AAGAGAACGGAGCAGA
7 R555W GCD
(12-CGG)
17 CAAGAGAATGGAGCAGA 12 GCD
16 CAAGAGAATGGAGCAG
16 AAGAGAATGGAGCAGA
ACD, Avellino corneal dystrophy; GCD, granular corneal dystrophy; LCD I, lattice corneal dystrophy type I; RBCD, Reis–
Bucklers corneal dystrophy.
*These probe numbers are used in fig 3A and fig 4A when showing the probe positions.
The sequences of the finally selected probes used in DNA chips are shown in bold.
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Figure 2 Hybridisation results according to
the probe length (A) and the hybridisation
time (B). The results are normalised for the
signal obtained with the wild-type sequence
versus that obtained with the mutant
sequence (W/M). ACD, Avellino corneal
dystrophy; LCD, lattice corneal dystrophy;
RBCD, Reis–Bucklers corneal dystrophy.
Table 3 bigh3 gene mutations in 98 participants
Mutations Sequences Exon number Number of cases Disease
R124H CGC to CAC
Heterozygotic 4 57 ACD
Homozygotic 10 ACD
R124C CGC to TGC
Heterozygotic 4 1 LCD I
R124L CGC to CTC
Heterozygotic 4 1 RBCD
R555W CGG to TGG 12 2 GCD
None No mutation 4 and 12 27
Total 98
ACD, Avellino corneal dystrophy; GCD, granular corneal dystrophy; LCD I, lattice corneal dystrophy type I; RBCD, Reis–
Bucklers corneal dystrophy.
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Figure 3 The first version of DNA chip designed for the detection of
mutations in the bigh3 gene. (A) The DNA chip design and probe
information. (B) Expected hybridisation results according to the types of the
corneal dystrophies (CDs). (C) Representative DNA chip hybridisation
results obtained using clinical samples. Position means the spotted position
markers always showing fluorescence to tell the spot positions accurately.
ACD, Avellino corneal dystrophy; LCD I, lattice corneal dystrophy type I;
RBCD, Reis–Bucklers corneal dystrophy.
Figure 4 The final version of DNA chip designed for the detection of
mutations in the bigh3 gene. (A) The DNA chip design using the probes
listed in table 2. (B) Expected hybridisation results according to the types of
corneal dystrophies, and the representative DNA chip hybridisation results
obtained using clinical samples. ACD, Avellino corneal dystrophy; GCD,
granular corneal dystrophy; LCD I, lattice corneal dystrophy type I; RBCD,
Reis–Bucklers corneal dystrophy.
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Preparation of target DNA
To prepare the target DNA, asymmetric PCR was carried out in
a 50 ml reaction mixture containing 16 buffer, 0.2 mM
deoxynucleotides triphosphates, 1 U Taq polymerase (Takara
Shuzo, Shiga, Japan), 100 ng chromosomal DNA, 3 mM
forward primer and 30 mM reverse primer. The 59 terminus of
each reverse primer used in asymmetric PCR was modified with
Cy5, Cy3 or FITC. The ACD and Ori 12 primer sets were used for
amplifying exons 4 and 12, respectively (table 1). By using a 10
times higher concentration of fluorescent-labelled reverse
primer, mainly single-stranded DNAs which are antisense to
the probes could be prepared. The ACD and Ori 12 primer sets
were used for amplifying exons 4 and 12, respectively (table 1).
The sizes of the amplified products from exons 4 and 12 were
147 and 318 bp, respectively(fig 1).
Hybridisation and data analysis
The spotted slides were steamed with boiling water for 1 min
and soaked in 70% (v/v) ice-cold ethanol to remove any non-
covalently bound oligonucleotides. To block the background
fluorescence, the unreacted aldehyde groups were treated with
sodium borohydride (NaBH4) solution. The PCR-amplified
target products (10 ml each) were directly added to the
hybridisation solution containing 66 saline/sodium phos-
phate/EDTA (SSPE) (0.9 M NaCl, 10 mM NaH2PO4?H2O,
1 mM EDTA, pH 7.4) and 20% (v/v) formamide.
Hybridisation was carried out by incubating at 30 C˚ for 4–6 h
in Array Chamber X (GenomicTree, Daejeon, Korea). After
washing with 36 SSPE for 5 min, 26 SSPE for 5 min and 16
SSPE for 5 min, the slides were scanned using arrayWoRx
(Applied Precision LLC, Issaquah, Washington, USA). Data
were analysed by ImaGene 6.0 software (BioDiscovery, El
Segundo, California, USA). The signal intensities were calcu-
lated by global normalisation for all positive spots, after
subtracting the background values from the median signal
intensities measured at 595 nm for Cy3, 685 nm for Cy5 and
530 nm for FITC.
RESULTS
The specific probes were designed on the basis of the sequences
of the normal and mutant bigh3 genes (fig 1 and table 2). First,
the probe length and the hybridisation time were optimised for
the diagnosis of CDs. It was concluded that the use of 15mer
probes and hybridisation at 30 C˚ for 4–6 h resulted in the
highest sensitivity and specificity for detecting the mutations in
exon 4 (fig 2). The wild type-to-mutant signal ratio, defined as
the ratio of the spot signal of the wild-type probe for normal
sequence (denoted as W) to that of each type of CD probe for
each mutated sequence (denoted as M), was used for the probe
optimisation. Each probe signal for the mutated sequence was
set to one, and the ratios of other probe signals to each mutated
sequence were calculated according to the probe length and the
hybridisation time. Figure 2A shows that single-base mismatch
could be discriminated successfully using a 13mer probe in the
homozygotic ACD, but the 15mer probes showed the highest
discrimination efficiency in different types of CDs. The
discrimination can be further enhanced by changing the probe
concentration. Hybridisation time was optimised with the
heterozygotic ACD and the homozygotic ACD samples. As
shown in fig 2B, hybridisation for 4–6 h was found to be
optimal for the highest sensitivity and specificity. The probes
finally selected are shown in bold letters in table 2.
The DNA chip-based diagnosis of CDs was performed using
blind tests for a total of 98 blood samples. The genotypes of
these samples were also determined by direct sequencing for
the verification of DNA chip results. DNA sequence analysis
showed that the 98 participants could be classified as 27
normal, 10 homozygotic ACD, 57 heterozygotic ACD, 1
heterozygotic LCD I, 1 heterozygotic RBCD and 2 GCD (table 3).
All microarray experiments were carried out in duplicate. The
results of DNA chip-based diagnosis matched 100% with those
obtained with direct DNA sequencing for all 98 samples. Four
types of CDs—namely, homozygotic ACD, heterozygotic ACD,
heterozygotic LCD I and heterozygotic RBCD—were detected in
96 samples. Figure 3 illustrates the DNA chip design, the
expected results and the representative DNA chip hybridisation
results. We also designed the probes for detecting GCD (two
samples) in an attempt to analyse the possibility of detecting
other types of CDs with DNA chip technology. Figure 4 shows
the applied DNA chip design and the representative results. The
DNA chip developed in this study could successfully diagnose
different types of CDs with 100% sensitivity, 100% specificity
and 100% positive predictive value. Table 4 summarises the
DNA chip hybridisation results of blind samples. It should be
noted that ACD is the most common type of CD detected in this
study. Even though we cannot truly claim the high specificity,
sensitivity and the predictive value for other types of CDs as the
number of samples was too small, the results clearly showed
Table 4 Summary of DNA microarray-based detection of the bigh3 gene in this study
Type Mutation
DNA microarray result
Sensitivity (%)* Specificity (%) Positive predictive value (%)`Positive Negative
Normal 27 0 100 100 100
Non-normal 0 71
ACD
Heterozygotic CGC/CAC 57 0 100 100 100
Non-heterozygotic 0 41
Homozygotic CAC 10 0 100 100 100
Non-homozygotic 0 88
LCD I
Heterozygotic CGC/TGC 1 0 100 100 100
Non-heterozygotic 0 97
RBCD
Heterozygotic CGC/CTC 1 0 100 100 100
Non-heterozygotic 0 97
GCD
Heterozygotic CGG/TGG 2 0 100 100 100
Non-heterozygotic 0 96
ACD, Avellino corneal dystrophy; GCD, granular corneal dystrophy; LCD I, lattice corneal dystrophy type I; RBCD, Reis–Bucklers corneal dystrophy.
*Sensitivity is defined as the number of true positives divided by the sum of true positives and false negatives.
Specificity is defined as the number of true negatives divided by the sum of true negatives and false positives.
`Positive predictive value is defined as the number of true positives divided by the sum of true positives and false positives.
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that the DNA microarray developed in this study can success-
fully distinguish between different types of CDs.
DISCUSSION
CDs have most often been categorised by their clinical
appearance examined by light and electron microscopes.
However, their appearance is variable, and thus is often
misdiagnosed. Recently, various types of mutations causing
different CDs have been reported,8–11 and the molecular basis for
the common and rare CDs is becoming apparent. However, the
disease phenotypes of CDs seem to be more diverse than
expected previously. Thus, it is desirable to diagnose them
accurately by direct DNA sequencing and related genetic
analyses. In this paper, we reported the development of a
DNA chip that allows simple, yet highly specific and accurate,
detection of mutations in the bigh3 gene causing the CDs. The
discrimination of the single-base mismatch from the perfect
match could be optimised by examining the different lengths
and concentrations of probes and the hybridisation time.
Through the blind tests, we were able to conclude that this
DNA chip-based method allows successful detection of various
mutation types of the CDs in 98 samples. Thus, the DNA chip
developed in this study allows specific and accurate diagnosis of
multiple types of b-aCDs, which should be useful in the present
clinical diagnosis and classification of b-aCDs.
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